Document is current
Any future updates will be listed below
-
Authors
Liu, Tung
Lin, Yu-Chieh
Chang, Pei-Chi
Hueng, Dueng-Yuan
Li, Yao-Feng
-
Funding
Funding for this research was provided by:
Tri-Service General Hospital (TSGH-E-111269)
National Science and Technology Council (113-2321-B-016 -005, 111-2314-B-016 -064 -MY3)
Taipei, Taichung, Kaohsiung Veterans General Hospital, Tri-Service General Hospital, Academia Sinica Joint Research Program (VTA113-T-4-2)
Ministry of National Defense Medical Affairs Bureau (MND-MAB-D-113167)
- License Information
-
More Information
Article History
Received: 14 February 2025
Accepted: 10 May 2025
First Online: 24 May 2025
Change Date: 15 June 2025
Change Type: Update
Change Details: This article has been updated to correct the funding information.
Declarations
:
: This study was approved by the Tri-Service General Hospital Ethics Committee (TSGHIRB No. A202205193), entitled "Brain Tumors Precision Medicine: From Clinical to Genetic and Artificial Intelligence, then Back to Clinical Applications". The research was conducted following the guidelines and regulations outlined by the Tri-Service General Hospital Ethics Committee.
: Informed consent to participate in this study was obtained from all participants. For the immunohistochemistry (IHC) evaluations, we used a human glioma tissue microarray (GL1001a) from Biomax, Inc., under Biomax’s standardized biobanking policies.
: Consent to publish was obtained from all participants. If participants were under 18 years of age, consent was obtained from a parent and/or legal guardian.
: The authors declare no competing interests.
